Publications
Detailed Information
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Slamon, Dennis J. | - |
dc.contributor.author | Neven, Patrick | - |
dc.contributor.author | Chia, Stephen | - |
dc.contributor.author | Fasching, Peter A. | - |
dc.contributor.author | De Laurentiis, Michelino | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Petrakova, Katarina | - |
dc.contributor.author | Bianchi, Giulia V. | - |
dc.contributor.author | Esteva, Francisco J. | - |
dc.contributor.author | Martin, Miguel | - |
dc.contributor.author | Nusch, Arnd | - |
dc.contributor.author | Sonke, Gabe S. | - |
dc.contributor.author | De la Cruz-Merino, Luis | - |
dc.contributor.author | Beck, J. Thaddeus | - |
dc.contributor.author | Pivot, Xavier | - |
dc.contributor.author | Sondhi, Manu | - |
dc.contributor.author | Wang, Yingbo | - |
dc.contributor.author | Chakravartty, Arunava | - |
dc.contributor.author | Rodriguez-Lorenc, Karen | - |
dc.contributor.author | Taran, Tetiana | - |
dc.contributor.author | Jerusalem, Guy | - |
dc.date.accessioned | 2022-03-22T09:11:15Z | - |
dc.date.available | 2022-03-22T09:11:15Z | - |
dc.date.created | 2020-05-12 | - |
dc.date.created | 2020-05-12 | - |
dc.date.created | 2020-05-12 | - |
dc.date.issued | 2020-02 | - |
dc.identifier.citation | New England Journal of Medicine, Vol.382 No.6, pp.514-524 | - |
dc.identifier.issn | 0028-4793 | - |
dc.identifier.other | 99183 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177223 | - |
dc.description.abstract | BACKGROUND In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopausal patients with hormone-receptor positive, human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer. Here we report the results of a protocol-specified second interim analysis of overall survival. METHODS Patients were randomly assigned in a 2;1 ratio to receive either ribociclib or placebo in addition to fulvestrant as first-line or second-line treatment. Survival was evaluated by means of a stratified log-rank test and summarized with the use of Kaplan Meier methods. RES U ITS This analysis was based on 275 deaths: 167 among 484 patients (34.5%) receiving ribociclib and 108 among 242 (44.6 /o) receiving placebo. Ribociclib plus fulvestrant showed a significant overall survival benefit over placebo plus fulvestrant. The estimated overall survival at 42 months was 57.8% (95% confidence interval [CI], 52.0 to 63.2) in the ribociclib group and 45.9% (95% CI, 36.9 to 54.5) in the placebo group, for a 28 /0 difference in the relative risk of death (hazard ratio, 0.72; 95% Cl, 0.57 to 0.92; P=0.00455). The benefit was consistent across most subgroups. In a descriptive update, median progression-free survival among patients receiving first-line treatment was 33.6 months (95% CI, 27.1 to 41.3) in the ribociclib group and 19.2 months (95% Cl, 14.9 to 23.6) in the placebo group. No new safety signals were observed. CONCLUSIONS Ribociclib plus fulvestrant showed a significant overall survival benefit over placebo plus fulvestrant in patients with hormone-receptor positive, HER2-negative advanced breast cancer. (Funded by Novartis; MONALEESA-3 ClinicalTrials.gov number, NCT02422615.) | - |
dc.language | 영어 | - |
dc.publisher | Massachusetts Medical Society | - |
dc.title | Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1056/NEJMoa1911149 | - |
dc.citation.journaltitle | New England Journal of Medicine | - |
dc.identifier.wosid | 000511997100006 | - |
dc.identifier.scopusid | 2-s2.0-85079075053 | - |
dc.citation.endpage | 524 | - |
dc.citation.number | 6 | - |
dc.citation.startpage | 514 | - |
dc.citation.volume | 382 | - |
dc.identifier.sci | 000511997100006 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | SCREENING TRIAL | - |
dc.subject.keywordPlus | DEATH VERIFICATION | - |
dc.subject.keywordPlus | LUNG | - |
dc.subject.keywordPlus | CT | - |
dc.subject.keywordPlus | NODULES | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | PARTICIPANTS | - |
dc.subject.keywordPlus | PROBABILITY | - |
dc.subject.keywordPlus | POPULATION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.